The Latest Trading Forecasts and Predictions

Safran is a long-established aerospace and defence group. Movements in the SAF stock price may reflect not only day-to-day market activity, but also Safran’s position within the French equity market and the aerospace and defence sector more broadly.

Credit Agricole’s share price is shaped by a mix of company-specific decisions and wider forces affecting the European banking sector.

Sanofi’s share price reflects the way a large, global pharmaceutical business interacts with markets on a day-to-day basis, responding to company updates, regulatory milestones and wider equity trends.

Orange is one of Europe’s largest telecommunications groups, and as of 8 January 2026, the stock trades within a well-defined range and broader European telecoms show relatively steady conditions. Past performance is not a reliable indicator of future results.

Airbus is one of the world’s largest aerospace manufacturers, with its share price shaped by a mix of commercial aviation cycles, government involvement and long-term industrial strategy. Discover the latest third-party AIR stock forecasts…

EU Stocks 50 (EU50) was trading around 5,721.0 as of 1:59pm (UTC) on 4 December 2025, within an intraday range of 5,687.4–5,729.9 on Capital.com’s platform. Prices remain close to recent Euro area benchmark levels, with related EU50 measures reported near 5,714.0 in early December.

EUR/CHF is trading around 0.93384 as of 11.28am UTC on 4 December 2025, within an intraday range of 0.93277–0.93430 on the Capital.com platform. The pair remains close to the levels seen in early December. Past performance is not a reliable indicator of future results.

Renk Group AG has remained in focus as traders track developments across the European defence sector and consider how recent company updates may be reflected in day-to-day price movements.

Hensoldt has remained an active name in the European defence sector, with its share price reflecting shifts in contract activity, budget trends and broader market conditions.

BioNTech’s share price has moved through a wide range in recent years, influenced by developments across its Covid-19 portfolio, oncology pipeline and broader trends within the biotechnology sector.